Memo

To: All Medical and Pharmacy Staff – Milstein Hospital only
From: E. Yoko Furuya, MD, Assistant Hospital Epidemiologist and Attending, Division of Infectious Diseases
       Christine Kubin, PharmD, Clinical Pharmacy Manager, Infectious Diseases
Date: 4/4/2008
Re: MODIFICATION OF INITIAL IV VANCOMYCIN ORDER IN ECLIPSYS TO 72 HOURS IN MILSTEIN HOSPITAL

MODIFICATION OF TIME PERIOD FOR INITIAL IV VANCOMYCIN ORDERS TO 72 HRS

A pilot is currently ongoing in Milstein Hospital to allow empiric IV vancomycin use without ID approval for the first 96 hours of therapy through the “Vancomycin Inj **INITIAL-96 HR STOP***” order in Eclipsys XA. This pilot has been well-received but has not limited IV vancomycin use to the degree intended. As a result, the time period for the initial IV vancomycin orders will be decreased to 72 hours.

- Effective Wednesday, April 16, 2008, initial orders for vancomycin IV for patients on ALL Milstein Hospital floors can be ordered in Eclipsys XA using the entry titled “Vancomycin Inj **INITIAL-72 HR STOP***”. This order will automatically default to a 3-day duration and will expire in 3 days (72 hours).
- This entry, if used appropriately for initial orders only, does not require ID approval.
- A re-assessment of the need for vancomycin must be performed within 72 hrs.
- If it is determined that vancomycin be continued, a new, routine vancomycin IV order MUST be entered and approval from Infectious Diseases for continued use of vancomycin IV MUST be obtained.
  - It is the responsibility of the medical team caring for the patient to ensure that a new order for vancomycin IV is entered in patients with a documented need for vancomycin therapy. Clinical pharmacy staff will assist in reminding the medical teams about this.
- **Repeated ordering of vancomycin IV using the “Vancomycin Inj **INITIAL-72 HR STOP***” entry at 72 hrs in an effort to circumvent ID approval will now be blocked by Eclipsys.

Vancomycin should continue to be used judiciously and appropriate cultures should be obtained prior to initiation of therapy. Vancomycin use will continue to be closely monitored. If you have any questions or concerns about this pilot project, please contact E. Yoko Furuya, MD (pager #80702) or Christine Kubin, PharmD. (pager #82356).